Beam Therapeutics sues Chinese biotech and VC-backed startup for alleged IP theft

Beam Therapeutics has filed a lawsuit in Massachusetts against Shanghai-based YolTech Therapeutics and U.S. startup Serapha Bio, alleging intellectual property theft. Beam claims its former scientist, Zi Jun Wang, secretly founded YolTech using stolen base-editing trade secrets. Serapha, which licensed YolTech's AATD therapy SERP-01 and raised $230 million, denies the allegations. The dispute highlights rising tensions between U.S. and Chinese biotech firms.

The lawsuit and Serapha's response

• ▪A lawsuit filed by Beam Therapeutics on Sept. 25 names YolTech Therapeutics' CEO, Yuxuan "Jensen" Wu, as a defendant alongside former scientist Zi Jun "Emma" Wang
• ▪Beam Therapeutics filed a lawsuit on September 25, 2026, in the U.S. District Court in Massachusetts against Chinese biotechnology company YolTech Therapeutics and its U.S. partner Serapha Bio
• ▪Beam Therapeutics is seeking court intervention to stop the misuse of its trade secrets and recover the value allegedly extracted unlawfully by YolTech Therapeutics and Serapha Bio

Allegations against former scientist Emma Wang

• ▪Five months after leaving Beam Therapeutics, Zi Jun "Emma" Wang filed patent applications on behalf of YolTech Therapeutics based on Beam's confidential and trade secret information
• ▪Beam Therapeutics accused Zi Jun "Emma" Wang of accessing electronic laboratory notebooks and records late at night and on weekends, departing sharply from her ordinary work as a scientist at Beam
• ▪Beam Therapeutics alleged that its former scientist, Zi Jun "Emma" Wang, secretly founded YolTech Therapeutics while still employed at Beam Therapeutics between 2021 and 2022

Comparison of the experimental therapies

• ▪Serapha Bio's experimental therapy, SERP-01, targets the same alpha-1 antitrypsin deficiency-causing mutation and changes a nucleotide at the same place in DNA as Beam Therapeutics' BEAM-302
• ▪YolTech Therapeutics licensed an experimental program for alpha-1 antitrypsin deficiency, codenamed SERP-01, to Serapha Bio for an undisclosed upfront payment
• ▪Beam Therapeutics' alpha-1 antitrypsin deficiency treatment, BEAM-302, is built on base editing technology that precisely changes a specific nucleotide in genetic code

Serapha Bio's corporate growth and funding

• ▪Serapha Bio appointed Kenneth Mills as CEO and Weston Miller as Chief Medical Officer to shepherd its alpha-1 antitrypsin deficiency program through clinical testing
• ▪Serapha Bio announced plans in June 2026 to go public through a reverse merger deal to develop its licensed alpha-1 antitrypsin deficiency therapy, SERP-01
• ▪Serapha Bio's development efforts were supported by $230 million in funding from investors including RA Capital Management and RTW Investments

Geopolitical context of the dispute

• ▪The intellectual property theft allegations by Beam Therapeutics against YolTech Therapeutics, made in a lawsuit filed Sept. 25, come amid escalating tensions between American biotechnology companies and their Chinese counterparts
• ▪Beam Therapeutics, based in Cambridge, Massachusetts, filed a lawsuit on Sept. 25 against Shanghai-based YolTech Therapeutics, highlighting cross-border intellectual property disputes in the gene-editing sector

Debatable claims

• ▪Serapha Bio should halt development of its SERP-01 therapy during the Beam lawsuit
• ▪U.S.-China biotechnology collaboration does more harm than good to American innovation